Meet Jessica in Emgality bubble

More is possible for patients like Jessicaa

AGE: 38
MIGRAINE FREQUENCY:
4 or more migraine headache days (MHDs)
per month
TREATMENT HISTORY:

  • Has implemented lifestyle modifications
  • Has tried various acute treatment options
  • Has tried 2 prior generic preventives

aHypothetical patient profile.

See results in patients with episodic migraine
See results in patients with chronic migraine

For your patients with episodic migraine (4-14 MHDs per month),

Emgality can give some patients the chance to be totally migraine-free for a month1

100% reduction in monthly MHDs from baseline was possible for a significantly greater mean percentage of patients on Emgality vs placebo over Months 1 to 61

EVOLVE-1: Response Rates
EVOLVE-2: Response Rates

In the REGAIN study, in patients with chronic migraine (≥15 headache days per month), the mean percentage of patients achieving 100% reduction in monthly MHDs from baseline was not significant vs placebo over Months 1 to 3.1

INDICATION
Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults.

SELECT IMPORTANT SAFETY INFORMATION
Contraindications

Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.

Review study design for EVOLVE-1 and EVOLVE-2
Review study design for REGAIN

Mom and son looking up in Emgality bubble

“Although I may not say it, I need more from my migraine preventive because my family depends on me. I’ve tried 2 generic medicines to help prevent migraine attacks, but I continue to have migraines at least 4 days per month.”

— Jessica, hypothetical patient with episodic migraine

We interviewed 4 real patients on Emgality to learn how taking a migraine preventive has impacted their lives. Watch their stories here.

bPatients were compensated for their time.


INDICATION
Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated for the preventive treatment of migraine in adults.

SELECT IMPORTANT SAFETY INFORMATION
Hypersensitivity Reactions

Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.

Download savings cardsc for your patients

cGovernmental beneficiaries excluded.

Subject to Terms and Conditions.


Reference: 1. Emgality [Prescribing Information]. Indianapolis, IN: Lilly USA, LLC.

Indications and Important Safety Information
Indications

Emgality is a calcitonin gene-related peptide (CGRP) antagonist indicated in adults for the:

  • Preventive treatment of migraine
  • Treatment of episodic cluster headache

Important Safety Information

CONTRAINDICATIONS
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.


WARNINGS AND PRECAUTIONS
Hypersensitivity Reactions
Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with Emgality in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of Emgality and initiate appropriate therapy. Hypersensitivity reactions can occur days after administration and may be prolonged.


ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and at least 2% greater than placebo) in Emgality clinical studies were injection site reactions.


Please see Full Prescribing Information, including Patient Information, for Emgality. See Instructions for Use included with the device.


GZ HCP ISI 10DEC2019